The Company announced it submitted a supplemental New Animal Drug Application (NADA) for NOCITA® (bupivacaine liposome injectable suspension) with the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM).
The Company plans on presenting at Jefferies 2018 Global Healthcare Conference on Tuesday, June 5, 2018 at 4:30 p.m. ET in New York City.
The Company will host a conference call and live audio webcast on Tuesday, November 11, 2014, at 8:30 a.m. ET, to discuss its financial results for the quarter ended September 30, 2014.
The Company announced the completion of a global licensing agreement for the development and commercialization of a novel oral CRTH2 antagonist for animal health indications.
The Company announced its first appearance at the Annual Veterinary Cancer Society meeting and plans to present data on monoclonal antibody oncology products in a series of presentations and a poster during the meeting.
The Company announced the full exercise of the underwriters’ option to purchase 675,000 additional shares of common stock in connection with the company’s previously announced public offering of 4,500,000 shares of common stock.
The Company announced the pricing of its public offering of 4,500,000 shares of its common stock at a price to the public of $9.25 per share.
The Company announced that it is commencing an underwritten registered public offering of shares of its common stock.
The Company met with several hundred veterinarians and veterinary staff at their IVECCS 2014 exhibit booth, at an exclusive Aratana Therapeutics reception and during an early morning breakfast to inform and educate the veterinary community on the novel therapeutics they are bringing to veterinary medicine.
The Company announced positive results from its pilot field study of AT-003 for managing post-operative pain in cats and dogs following surgery.
The Company announced that it will present at the Morgan Stanley Global Healthcare Conference, to be held September 8-10, 2014, at the Grand Hyatt in New York City.
The Company announced its second quarter 2014 results and plans to host a conference call August 12, 2014 at 8:30 a.m. ET.
The Company will host a conference call and live audio webcast on August 12, 201, at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2014.
The Company today announced that it has appointed Irvine O. Hockaday, Jr. to its Board of Directors where he will also serve on the Nominating and Corporate Governance Committee.
Start-Ups Work on Biotech Drugs for Pets, by Andrew Pollack, was a feature article in The New York Times online August 2, 2014.
The Company announced that it has filed for a product license from the United States Department of Agriculture (USDA) for AT-014, a novel her2/neu-directed cancer immunotherapy licensed exclusively from Advaxis, Inc. (NASDAQ: ADXS) for the treatment of canine osteosarcoma and other cancers.
Denali, a therapy dog, inspires patients in hospitals, but is also an inspiration himself.
The Company announced the appointment of former Cephalon, Inc., executive Robert P. Roche, Jr. to its Board of Directors.